Slides
Page 1
Corporate Presentation November 2025
Page 2
2 Corporate Presentation | November 2025 Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Harrow, Inc. (the “Company” or “Harrow”). Some of these risks and uncertainties include, but are not limited to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration related to compliance and quality plans at our resourcing facility in New Jersey; and physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Harrow expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. The Company’s compounded formulations are not FDA approved. All trademarks, service marks and trade names included in this presentation are the property of their respective owners. This presentation refers to non-GAAP financial measures, specifically adjusted EBITDA, Core Results, such as core gross margin, core net income and core diluted net income per share, and equity values of equity positions in non-controlled investments. A reconciliation and/or further description of any non-GAAP measures with the most directly comparable GAAP measures are included in the Company’s Letters to Stockholders, available on its website. All content included in this presentation is intended for investors and the investment community and is not intended as marketing material or for use by healthcare professionals and their patients.
Page 3
3 Corporate Presentation | November 2025 Payer Type: Disease Origin: Product Category: Harrow – A Leading Provider of Ophthalmic Disease Management Solutions in North America Largest U.S. portfolio of ophthalmic products broadly covering the ophthalmic anatomy Key revenue drivers are best- in-class products with large market opportunities Scalable commercial platform with an innovative market access & distribution model Delivery Types: Injectable | Topical | Device Buy & Bill | Branded | Generic Over-the-Counter | Compounded Anterior | Posterior | Ocular Surface Commercial | Government | Cash Harrow was founded to advance the standard of eye care and deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes MELT-300 | Sedation 2028 • Access and affordability are foundational Harrow commitments • Access for All programs ensure eligible patients can receive Harrow products for as low as $0, or a maximum of $59 • Ability to scale through future acquisitions that fit within the existing Harrow commercial infrastructure | Dry Eye Disease | PF Corticosteroid | Anti-VEGF Mid-2026 | Ocular Anesthesia | Anti-VEGF Mid-2027 Drug Candidate
Page 4
Corporate Presentation | November 2025 4 Harrow’s Ophthalmic Disease Management Solutions SPECIALTY PRIMARY RETINA DRY EYE PharmaPack Surgery PharmaPack Pressure SURGICAL RARE & SPECIALTY PRODUCTS RARESPECIALTY * TRIESENCE is sold by the Retina Team, primarily for visualization during vitrectomy, and by the Surgical Team, primarily for controlling ocular inflammation * *
Page 5
5 Corporate Presentation | November 2025 Investment Highlights Recent Launches and 2025–2028 Pipeline Accelerating Growth Trajectory In September 2025, Harrow agreed to acquire Melt Pharmaceuticals, including MELT -300, a non-IV & non-opioid for procedural sedation BYQLOVI (Topical Steroid) Q1 2026 launch BYOOVIZ (Lucentis Biosimilar) mid -2026 launch OPUVIZ (EYLEA Biosimilar) mid -2027 launch MELT-300 drug candidate expected to launch in 2028 • Large market; category-leading potential; 22% revenue growth Q3 2025 vs Q2 2025 o Agreements signed with several leading national payers • 20% growth in revenue in Q3 2025 vs Q2 2025 • Nearly half (46%) of accounts ordering IHEEZO year-to- date are new customers • 67% growth in unit demand Q3 2025 vs Q2 2025 • Q4 launch into the largest market opportunity with Reimbursement confirmed • High margin and stable workhorse product portfolio • Hired VP of portfolio • Harrow Access for All (HAFA) launch in Q4 2025 Rare & Specialty Products
Page 6
6 Corporate Presentation | November 2025 Our Vision is to Become the Next Great US Ophthalmic Company 1. Founder Leadership 2. Base Business + Acquisitions = Long -Term Growth 3. Operational Execution 4. Pipeline Development • “Harrow was founded in 2012 with $1 million of capital and $1 trillion of determination” … Mark L. Baum • Founders lead all business development activities, supported by Harrow SMEs • Disciplined; fast-moving and dynamic; seize ground and adapt 1 • Several best-in-class large market products are going, growing, and cash flowing - with more to come • Most active buyer or licensor of ophthalmic assets in the US market • Partner of choice for ophthalmic product developers; proven commercial capabilities 2 • Eyecare professionals who know Harrow appreciate our partnership • Premier commercial talent want to join Harrow; culturally, merit- focused; not a place to “hide out” • Patient and prescriber-centric principles are reflected in access and affordability programs 3 • Low-risk approach • Near-term launches and potential large market NDA approvals on deck • Opportunity to extend reach outside of the US and core ophthalmic business through partnerships 4
Page 7
7 Corporate Presentation | November 2025 Financials and Commercial Overview
Page 8
8 Corporate Presentation | November 2025 Q3 2025 Key Financial Metrics (in thousands) (1) Adjusted EBITDA is defined as net income (loss), excluding the effects of stock-based compensation and expenses, impairment of intangible assets, interest, taxes, depreciation, amortization, investment (income) loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net income (loss) as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs. $74,290 in cash and cash equivalents as of September 30, 2025 Consolidated Revenues Adjusted EBITDA $5,715 $11,378 $13,017 $28,119 $40,327 $37,753 20 21 22 23 24 YTD $22.7 Adjusted EBITDA in Q3 2025 Operating expenses expected to remain stable $48,871 $72,476 $88,595 $130,193 $199,614 $280,000 20 21 22 23 24 25 $270,000 - ‘25 Guidance YTD 25 $183.2 Q1 25 $47.8 Q2 25 $63.7 Q3 25 $71.6
Page 9
9 Corporate Presentation | November 2025 Q3 2025 Key Growth Drivers (1) Adjusted EBITDA is defined as net income (loss), excluding the effects of stock-based compensation and expenses, impairment of intangible assets, interest, taxes, depreciation, amortization, investment (income) loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net income (loss) as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs. $18.6M $18.3M $5.2M $21.5M Q3 2025 Revenue Q2 2025 Revenue Q1 2025 Revenue Specialty Branded $21.5M $5.2M $1.0M $20.5M $22.6M $21.9M $6.9M $20.1M 2025 Guidance $270M - $280M • October all-time high in scripts written • Best-in-class refill rate • Potential coverage switch volume in Q4 • Large new Q4 orders • Q4 is the strongest period driven by increased stocking & demand • New leadership & strategies in place • TRIESENCE launched in ocular inflammation; positive reimbursement • New leadership in Q4 • Mature portfolio of cash pay ophthalmic products beloved by over 15,000 US eyecare professionals
Page 10
10 Corporate Presentation | November 2025 Commercial Overview 1McCann, Paul, et al. “Prevalence and incidence of dry eye and meibomian gland dysfunction in the United States.” JAMA Ophthalmology , vol. 140, no. 12, 1 Dec. 2022, p. 1181, https://doi.org/10.1001/jamaophthalmol.2022.4394 and “U.S. Dry Eye Syndrome Treatment Market Size Report, 2030.” U.S. Dry Eye Syndrome Treatment Market Size Report, 2030 , www.grandviewresearch.com/industry -analysis/us -dry-eye-syndrome -treatment -market-report. Accessed 31 Oct. 2025. 2Includes Age Related Macular Degeneration, Diabetic Retinopathy, Retinal Detachment; https://preventblindness.org/amd -prevalence -vehss/, https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2806093 , https://www.ncbi.nlm.nih.gov/books/NBK551502/ . 3See Ocular Surgery Introduction slide. 4Figure shown for ocular allergies; patients may overlap with those who have infections and other relevant conditions; Leonard i A, Castegnaro A, Valerio AL, Lazzarini D. Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population -based study. Curr Opin Allergy Clin Immunol. 2015 Oct;15(5):482 -8. doi: 10.1097/ACI.0000000000000204. PMID: 26258920. Market Segment Complete portfolio of dry eye solutions Drive increased depth & breadth; leverage new preferred coverage Pan-retina Strategic account activation Peri-operative Leverage injectable and topical steroid experience; introduce our program and activate the relationship Everyday ophthalmic needs New leadership, employ scalable investment model Dry Eye Retina Surgical Rare & Specialty Brands 1 2 3 4 Prevalence Aim Commercial Priorities 16-20M1 29-30M2 7-8M3 20-50M+4 Mkt Penetration
Page 11
11 Corporate Presentation | November 2025 Addressing Dry Eye Disease
Page 12
12 Corporate Presentation | November 2025 Addressing Dry Eye Disease Harrow has a broad portfolio of products addressing the large and growing market for anterior segmentinflammation and dry eye disease FDA-approved to treat the signs & symptoms of Dry Eye Disease Vision to become the #1 cyclosporine-based DED prescription and eventually, the #1 DED prescription in the US FDA-approved for use in the treatment of steroid- responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye Patented through 2039, FRESHKOTE® Preservative Free (PF) is a lubricant eye drop that contains povidone and polyvinyl alcohol to supplement the eye's natural lipid layer, helping to reduce tear evaporation and retain eye surface moisture
Page 13
13 Corporate Presentation | November 2025 The first and only water-free cyclosporine to treat the signs and symptoms of dry eye disease • In a pre-clinical ex-vivo corneal penetration study, VEVYE's vehicle delivered ~22x more cyclosporine into the cornea than Restasis • Rapid Onset – fastest working immunomodulator for dry eye demonstrated • Clinically meaningful and statistically significant improvement in total corneal fluorescent staining by Day 15 with lasting benefit out to 56 weeks • Well-tolerated, with 99.8% of patients experiencing no or mild instillation pain • Orange book-listed patents with expiry in 2039 VEVYE – A Best-in-Class Solution for Dry Eye Disease DED Patient Population Dry Eye prevalence is continuing to grow with aging populations, increased screen time and poor diets • 37.1M patients globally are estimated to be suffering from DED • 28.1M treating their dry eye with some form of medication • 16.4M people in the US have been diagnosed with DED • 9.1M treating dry eye with an Rx medication o 92% of patients remain un- or under- treated due to limited efficacy and poor tolerability of many products on the market o Historically, many DED patients switch between therapies, leading to poor adherence and refill rates
Page 14
14 Corporate Presentation | November 2025 VEVYE Q3 2025 Key Metrics $5,186,000 $15,962,000 $21,500,000 $18,600,000 $22,600,000 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 VAFA Began VEVYE Quarterly Revenue 22% Growth Q3-25 vs. Q2-25 (1) As of 2Q25, Harrow pharmacy partners have discontinued reporting VEVYE prescription data to third-party aggregators, like IQVIA. As a result, publicly available pay-for-data sources may no longer reflect VEVYE’s actual market performance . • Sustained Momentum: 22% increase in revenue in Q3 2025 vs Q2 2025 • Prescriber Adoption Growth: 36% quarter-over- quarter increase in prescribing physicians • Surpassing Key Competitors: Passed CEQUA in market share in Q2, now ahead of MIEBO NRx in four markets • Coverage Wins: New preferred product status commercial coverage set to begin January 1, 2026, with the largest commercial pharmacy benefit manager • Commercial Expansion: targeting 10 new territories to support the next phase of national expansion in Q4 2025; expect to reach 9 -10 by Q2 2026 • The compounding impact of NRx & high refill rates is expected to drive sustained revenue growth
Page 15
Corporate Presentation | November 2025 15 VEVYE Outlook GOALS • Establish VEVYE as the leading cyclosporine - based Rx treatment • Achieve leadership in anti -inflammatory Rx category • Become the #1 branded treatment for Dry Eye Disease PRIORITIES Accelerate growth; account breadth & depth • Deepen use among current VEVYE ECPs • Drive trial among new ECPs • Strengthen ECP and patient experience via improved access and new coverage Dry Eye Disease Branded & Generic TRx (’24 -’25) IQVIA Xponent Plantrak weekly data and PhilRx data, week ending 9/26/25 Branded Generic 2025 P13W C13W 1,208k 1,341k 389k 415k Chg % +11% +7% VEVYE TRx Share (’25) IQVIA & PhilRx data, week ending 9/26/25 0 20,000 40,000 60,000 80,000 100,000 120,000 Jan Mar May Jul Sep Nov Jan Mar May Jul Sep TRx 2024 5.20% 7.80% 10.50% Q1 2025 Q2 2025 Q3 2025 Doubled Market Share in 2 Quarters
Page 16
16 Corporate Presentation | November 2025 Retina (Anesthetics, Therapeutics)
Page 17
17 Corporate Presentation | November 2025 IHEEZO Overview • First approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride • First branded ocular anesthetic approved for the U.S. market in nearly 14 years • IHEEZO Reimbursement: o Permanent J-Code (J2403) o Transitional pass-through status through April 2026 for ASC • >12 million annual U.S. ocular procedures requiring ocular surface anesthesia • Inactive ingredient hydroxyethyl cellulose, typically used in eye lubricants/tears • Two Orange Book listed patents; latest expiring in 2039 Sterile, single-patient-use, physician-administered, ophthalmic gel preparation for ocular surface anesthesia, approved by the FDA in September 2022 IHEEZO clinical studies demonstrated : ~1-1.5 Min. IHEEZO worked rapidly IHEEZO had lower pain scores vs tetracaine IHEEZO provided sufficient anesthesia to successfully perform the surgical procedure ~22 Min. No patient dosed with IHEEZO required a supplemental treatment to complete the surgical procedure
Page 18
18 Corporate Presentation | November 2025 IHEEZO Q3 2025 Key Metrics (1) Source: IQVIA 867 data Q3 Highlights: • Nearly half (46%) of accounts ordering YTD are new customers • Majority of new accounts were retina practices • Agreements with all 4 major GPOs in retina space • 85% customer reorder rate Priorities • Accelerate growth via breadth & depth • Deepen use among current retina accounts • Drive trial among new retina specialists • Explore options to strengthen physician and patient experience via improved access 15,096 38,940 29,991 48,76534,368 50,565 49,130 2024 2025 IHEEZO Quarterly Customer Unit Demand (1) (May 2023 Launch) Q1 Q2 Q3 Q4 Full Year 2024: 128,685 Through Q3 2025: 138,270
Page 19
Corporate Presentation | November 2025 19 (1) Data on visualization of vitrectomy obtained from Definitive Health 2023; data on posterior uveitis obtained from MedScape . TRIESENCE Description: (1) • The only FDA-approved preservative -free synthetic corticosteroid with separate reimbursement in all traditional settings of care Supply Chain: • Five-year supply agreement with current CMO • Next-generation product development underway Reimbursement and Coverage: • Product-specific J-Code (J-3300) • Surgical and non-surgical indication affords unique reimbursement benefits • Pass-through status granted by CMS effective April 1, 2025 Intellectual Property: • Orange Book–listed patents, expiring in 2029 Development: • Next generation version of TRIESENCE in development and expected in the market prior to patent expiration Q3 Highlights: • 4x growth since re -launch • 67% volume growth 3Q vs 2Q • 53% of all Q3 accounts are new customers Priorities: • Oct 1 launch into ocular inflammation market, the largest single market for the product • Paid claims in ocular inflammation surgical cases now confirmed • Accelerate growth via breadth & depth o Deepen use among current retina accounts o Drive trial among new retina specialists o Explore options to strengthen physician and patient experience via improved access
Page 20
20 Corporate Presentation | November 2025 Best-in-Class anti-VEGF Biosimilars BYOOVIZ (ranibizumab -nuna) 0.05mL injection, the first FDA- approved LUCENTIS biosimilar • Indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV) • Interchangeability status Harrow's U.S. launch expected in mid-2026 OPUVIZ (aflibercept -yszy) 0.05mL injection, an FDA-approved EYLEA biosimilar • Indicated for the treatment of patients with Wet AMD, Macular Edema following RVO, DME, and Diabetic Retinopathy (DR) • Interchangeability status Harrow's U.S. launch expected in second half 2027 Fits in with existing commercial infrastructure & clinical synergy with IHEEZO (ocular anesthetic) & TRIESENCE (corticosteroid) Recently entered into an agreement with Samsung Bioepis to acquire U.S. commercials rights to portfolio of ophthalmic biosimilars, including BYOOVIZ® (Lucentis Biosimilar) and OPUVIZ (Eylea Biosimilar) Harrow intends to take over commercialization of BYOOVIZ and OPUVIZ upon completion of transfer of commercialization rights e xpected by the end of 2025. Trademarks are Biogen’s.
Page 21
21 Corporate Presentation | November 2025 U.S. Ophthalmic Market Share-Anti-VEGF’s ~8.5M Units Across All Products 191 M BYOOVIZ (Lucentis) & OPUVIZ (Eylea) offer a compelling value proposition and cost -effective alternative to current Anti -VEGF therapies & compounded Avastin : • An FDA-approved, clinically-validated on- label option offering consistency, proven safety, and reliable supply chain and pricing predictability • Both products have interchangeability status • Final products to be manufactured in the U.S. • Well-positioned as a lower -cost anti-VEGF therapy offering an affordable and accessible alternative for patients • Anti-VEGF market is dominated by EYLEA, LUCENTIS, VABYSMO, and compounded Avastin (used off-label) • Annual spending for current therapies in the U.S. under Medicare Part B exceeds $4.2B2 making it among the most expensive drug categories in the U.S. 2,550,000 850,000 1,445,000 680,000 2,550,000 425,000 Eylea Eylea HD Vabysmo Lucentis Avastin Biosimilars Unit Volume1
Page 22
22 Corporate Presentation | November 2025 Rare & Specialty Product Portfolio
Page 23
23 Corporate Presentation | November 2025 Rare & Specialty Product Portfolio “Workhorse” products in U.S. optometry and ophthalmology offices • New commercial leadership to oversee portfolio of products • New access program (HAFA) to launch in Q4 • Significant opportunity – Harrow products currently make up <1% of market volume • Plan: efficient, scalable investment to drive profitable growth in future quarters • This portfolio of products recently generated $10M in quarterly revenue Antihistamine, Antibiotics , and Antibiotic + Steroid Combination Only FDA-approved Ophthalmic Antifungal Product Harrow Authorized Generics Steroids, NSAIDs, and Anti-inflammatories Only FDA-approved Product for Vernal Keratoconjunctivitis Glaucoma and IOP Control
Page 24
24 Corporate Presentation | November 2025 Surgical
Page 25
25 Corporate Presentation | November 2025 Ocular Surgery Introduction AMBITION We are “planting a flag” to establish Harrow’s portfolio as the peri-operative solution PRIORITIES Focus early launch phase on displacing alternatives in the injection & topical peri - operative setting • Refine targeting to ensure highest possibility of competitor displacement • Drive depth and breadth in injectable segment • Prepare for additional product opportunities to maximize portfolio value US Ocular Surgery Volume (‘000) Harrow intelligence, “All Other” includes Retinal Surgery, Strabismus/Eye Muscle Surgery, Oculoplastic Surgery 4,500 1,700 850 50 807 Cataracts Glaucoma Refractive Corneal Transplant All Other Primary Focus Secondary Focus Not a Focus ~500k steroid injections (est) ~4M use topical steroids (est) [1] The Future o f Cataract Surgery - iOR [2] Impact of reduced elective o phthalmic surgical volume on U.S [7] Glaucoma Surgery Devices Market Size & Forecast [2033 [4] Market Scope: Refractive Surgery to Grow 9.6% a Year Through [5] Refractive Reports - Market [9] Corneal Transplants - UAB [2] Impact of reduced elective ophthalmic surgical volume on U.S US Oculoplastic Surgery Market Size & Outlook, 2023-2030
Page 26
26 Corporate Presentation | November 2025 Building a World-Class Surgical Portfolio Supportive Best-in-Class Products Best-in-Class Anti-Inflammatories Establish TRIESENCE as a first- line treatment preservative- free, injectable, and titratable option for ocular inflammation Position BYQLOVI as the first differentiated topical steroid on the market in over a decade Topical NSAIDs Topical Antibacterial MELT-300 Drug Candidate Sublingual Sedation
Page 27
27 Corporate Presentation | November 2025 Focusing on the Ocular Inflammation Market • Encouraging physician feedback and early market traction — initial utilization trends indicate strong reception of TRIESENCE in the surgical setting, reinforcing its clinical value and commercial potential • TRIESENCE is the most affordable FDA-approved injectable ocular steroid • Patient's out-of-pocket costs can be as low as ~$37 for government & private payers • TRIESENCE has broad coverage: o 96% covered lives o 6% of patients require prior authorization o Reimbursement in all care settings (ASC, HOPD, and office) • Eliminates the need for patient- or caregiver-administered steroid drops, improving compliance and reducing the overall post-operative burden • Harrow’s first product, a compounded combination product containing triamcinolone acetonide, has sold over 1.5 million units Harrow internal data Focus on establishing TRIESENCE as a first -line treatment option for ocular inflammation unresponsive to topical steroids
Page 28
28 Corporate Presentation | November 2025 BYQLOVI – Best-in-Class Steroid Recent acquisition leveraging Harrow’s commercial infrastructure Description: • BYQLOVI is an FDA-approved steroid to treat inflammation and pain after ocular surgery • Super potent and unique steroid: BYQLOVI is the only FDA-approved ocular steroid that utilizes clobetasol • Best-in-class features: robust clinical efficacy, proven safety profile, dosing (BID) o Robust clinical efficacy: over 80% of patients reported pain-free on the 4th day following surgery o Proven safety profile: low incidence of IOP elevation o Dosing: BID Market: • > 7M annual ophthalmic surgeries in the U.S. Intellectual Property: • 2 Orange Book–listed patents, expiring in 2036 Launch in Q1 2026 Global Data, US Ophthalmic Procedures Count and Forecast to 2030 (Dec 2023)
Page 29
29 Corporate Presentation | November 2025 MELT-300: IV- and Opioid-Free Procedural Sedation Fixed dose sublingual tablet combining 3 mg midazolam + 50 mg ketamine (non-opioid), two known and proven FDA-approved molecules in a novel form “MELT-300 is simple and sublingual, shares the benefits of midazolam and ketamine, with additive sedation effect.” – Anesthesiologists and Ophthalmologists 6 Technology • Dissolves in seconds under the tongue, using proprietary Zydis® manufacturing technology exclusively licensed from Catalent • Zydis® technology has been used in over 35 NDA-approved products spanning almost three decades • Easy, quick absorption inthe sublingual mucosa resulting in rapid, systemic circulation and better bioavailability profile than via GI tract absorption Administration Synergy • Midazolam offsets the negative effects of ketamine o According to Market Scope reports, cataract surgeries are expected to be greater than 5 million annually in the US and over 20 million globally in the coming years1 Initial Target of Cataract Surgery with the Potential to Expand With an expanded label, MELT-300 could impact over 100 million short-duration procedures in a number of large markets2 Targets and Expansion
Page 30
30 Corporate Presentation | November 2025 Agreement with U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment* (SPA) for the MELT-300 Phase 3 Study Covering: Next Steps For MELT-300 *SPA is a process in which sponsors may ask to meet with FDA to reach agreement on the design and size of certain clinical trials to determine if they adequately address scientific and regulatory requirements that could support, but not guarantee, marketing approval. An SPA agreement indicates concurrence by FDA with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, and planned analyses) for a study intended to support a future marketing application. 7 Based on discussion with its regulatory consultants, the Company believes that it has met the requirements to only have one Phase 3 study. FDA agreed that the Phase 3 study would “adequately address the objectives necessary to support a regulatory submission” Additionally, FDA agreed with the results from our thorough QTc study that MELT-300 did not alter normal heart rhythm Anticipated Closing NDA Submission Potential FDA Approval Potential Launch Q4 2025 H1 2027 H1 2028 H2 2028 Study Design and Planned Analysis Study Statistical Approach Primary and Secondary Endpoints
Page 31
31 Corporate Presentation | November 2025 Ensuring Access, and Affordability
Page 32
32 Corporate Presentation | November 2025 VEVYE Access For All (VAFA) 1. * For eligible commercially insured patients, after meeting a deductible, out-of-pocket costs will be $0. And – Harrow will reduce insurance co-pays by up to $400! 2. ** Subject to terms and conditions for eligible patients, please visit harrowconnects.com to learn more (e.g., Medicare Part-D Opt-Out language, etc.). 3. ***Subject to specific insurance plans for eligible patients, and Medicare-Part D opt-out through PHILRx. • Remove Barriers to Access for Patients and Providers • No prior authorization submission delays for eligible patients • Enhance Prescriber Confidence and Improve Commercial Coverage • Increase Profitability and Improve Gross to Net (GTN) Eyecare professional prescribes through EMR Specialty pharmacy partner adjudicates Rx and dispenses VEVYE Predictable Patient Experience : VEVYE is dispensed, regardless of insurance coverage, for $0-$59 per bottle 1-3*
Page 33
Corporate Presentation | November 2025 33 Harrow Access For All (HAFA) Building on the Success of VEVYE Access for All 'The Amazon for Ophthalmology’ A seamless and unified platform and access point for a portfolio of Ophthalmic medicines Eligible commercially insured patients may pay as little as $0 with out-of-pocket costs for all eligible patients capped at $59 Branded Products (Q4 2025) Generic (H1 2026) Compounded (2027) Harrow Portfolio Available Through a Single Trusted Access Point Accessible and Affordable for All Patients White-glove service to streamline prior authorizations and reduce administrative burden, the platform helps prescribers save time, provide visibility, and improve efficiency
Page 34
34 Corporate Presentation | November 2025 Commitment to Supporting Mission Trips We are proud to have never turned down an opportunity to provide Harrow products to ophthalmologists and optometrists helping to give the gift of sight to our fellow brothers and sisters in the U.S. and across the globe. Mark L. Baum, Chief Executive Officer and Founder To date, in 2025, Harrow has committed donations to help nearly 5,000 patients in over 18 countries. During 2024, Harrow’s donations helped approximately 17,000 patients in over 38 countries. See Intl (Honduras) April 2024 Eye Doctors of Lancaster (Africa) October 2024 Nevis Eye Care (West Indies) November 2024 Health in Sight Missions (Honduras) February 2025
Page 35
35 Corporate Presentation | November 2025 Compounded Products
Page 36
36 Corporate Presentation | November 2025 ImprimisRx *Excludes revenue From DEXYCU® in all years; 2023 revenues reflect sale of Company’s non-ophthalmic business. Revenues* (Dollars in thousands) ImprimisRx’s revenue is for compounded products, which are not FDA-approved • Leading U.S. ophthalmic-focused compounding business • More than 15,000 U.S. customers • 50-state dispensing capabilities • Broad product portfolio with a concentration on supporting surgical interventions • Through “Project Beagle,” Harrow is transitioning patients from compounded products to equivalent or alternative FDA- approved products from Harrow’s branded portfolio $48,475 $69,104 $82,013 $79,935 $83,499 $61,575 20 21 22 23 24 YTD
Page 37
37 Corporate Presentation | November 2025 1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 Harrow.com Mike Biega Vice President of Investor Relations & Communications mbiega@harrowinc.com Direct: 617-913-8890